Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)

Revumenib led to high remission rates with a predictable safety profile in R/R <i>KMT2Ar</i> acute leukemia. To our knowledge, this trial represents the largest evaluation of a targeted therapy for these patients.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2024-08-09
DOI
https://doi.org/10.1200/jco.24.00826
Citations
150
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
68.16

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)

Kate Madigan, Ofir Wolach, Andre C. Schuh, Elie Traer et al.
150 citations
Journal of Clinical Oncology
Acute Myeloid Leukemia Research
68.16
article

Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)

Kate Madigan, Ofir Wolach, Andre C. Schuh, Elie Traer, Maël Heiblig, Andrew H. Wei, Manish R. Patel, C. Michael Zwaan, Shaun Fleming, Nicole McNeer, Martha Arellano, Ashish Bajel, C. Michel Zwaan, Neerav Narendra Shukla, Boaz Nachmias, Giovanni Marconi, Ioannis Mantzaris, Michael J. Thirman, Alexander E. Perl, Ibrahim Taha Aldoss, Matthew Greenwood, Carolyn Grove, Yakov Chudnovsky, Branko Cuglievan, Ghayas C. Issa, Yu Gu, John F. DiPersio, Eytan M. Stein, Christine M. McMahon, Richard Maury Stone, David S. Dickens, Nguyễn Văn Huy, Chetasi Talati, John Byrd, James S. Blachly, James A. Whitlock, Gabriel N. Mannis, Jing Chen, Paul J. Shami, Himalee Sabins, Montserrat Arnan-Sangerman, Tibor Kovacsovics, Rebecca G. Bagley, P Fernandez, Paul J. Shami
article en
150 citations

Abstract

Revumenib led to high remission rates with a predictable safety profile in R/R <i>KMT2Ar</i> acute leukemia. To our knowledge, this trial represents the largest evaluation of a targeted therapy for these patients.

Journal of Clinical OncologyVol. 43(1)
The University of Sydney (AU), Albert Einstein College of Medicine (US), City Of Hope National Medical Center (US), Memorial Sloan Kettering Cancer Center (US), Montefiore Medical Center (US), The University of Texas MD Anderson Cancer Center (US), Emory University (US), Oregon Health & Science University (US), Washington University in St. Louis (US), University of Utah (US), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US), Royal North Shore Hospital (AU), Huntsman Cancer Institute (US), Sir Charles Gairdner Hospital (AU), University of Chicago (US), University of Colorado Health (US), University of Iowa Stead Family Children’s Hospital (US), City of Hope (US), Dana-Farber Cancer Institute (US), Princess Máxima Center (NL), Erasmus MC - Sophia Children’s Hospital (NL), Goodyear (United States) (US), Synta Pharmaceuticals (United States) (US), Montefiore Einstein Comprehensive Cancer Center, The Ohio State University (US), University of Pennsylvania (US), Stanford University (US)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, Yale University, Gilead Sciences, Celgene, Carnegie Mellon University, Foghorn Therapeutics, Agios Pharmaceuticals, CTI Biopharma, Incyte, Calithera Biosciences, Syndax Pharmaceuticals, Eisai, Astellas Pharma, Genesis Pharma, Servier, Ono Pharmaceutical, Genentech, Daiichi Sankyo Europe
Good health and well-being
Openalex Percentile: Top 0%
Acute Myeloid Leukemia Research
68.16
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.